ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

January 13, 2014 8:00 AM UTC

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell $3.58 (15%) to $20.37 on Thursday after disclosing in an SEC filing that FDA has not yet discussed with the company proposed labeling or postmarketing requirements for Feraheme ferumoxytol, even though an sNDA for the anemia drug has a Jan. 21 PDUFA date. AMAG is seeking to expand Feraheme's label to include treatment of all adult patients with iron deficiency anemia who have failed or could not tolerate oral iron treatment.

Last week, AMAG was off $3.14 (13%) to $20.79...